Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.
about
Overutilization of proton-pump inhibitors: what the clinician needs to knowOverprescribing proton pump inhibitorsPharmacological interventions on early functional gastrointestinal disordersPrevention of stress-related ulcer bleeding at the intensive care unit: Risks and benefits of stress ulcer prophylaxisClostridium difficile in the ICU: the struggle continuesSystematic review: the use of proton pump inhibitors and increased susceptibility to enteric infectionOperationalising factors that explain the emergence of infectious diseases: a case study of the human campylobacteriosis epidemicAssociation between NSAIDs and Clostridium difficile-Associated Diarrhea: A Systematic Review and Meta-AnalysisEpidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative ReviewClostridium difficile: A healthcare-associated infection of unknown significance in adults in sub-Saharan AfricaAntimicrobial drugs and community-acquired Clostridium difficile-associated disease, UKCommunity-associated Clostridium difficile infection and antibiotics: a meta-analysisThe roles of injury and nonsteroidal anti-inflammatory drugs in the development and outcomes of severe group A streptococcal soft tissue infectionsEvolution of primary care databases in UK: a scientometric analysis of research outputToxins From the GutClostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventionsThe changing epidemiology of Clostridium difficile infectionsHospital acquired infectionEffects of delayed NSAID administration after experimental eccentric contraction injury – A cellular and proteomics studyAutomated surveillance of Clostridium difficile infections using BioSense.Assessment of Clostridium difficile-associated disease surveillance definitions, North Carolina, 2005.The challenges posed by reemerging Clostridium difficile infection.[Clostridium difficile infections in geriatric patients].Clostridium difficile infection: guideline-based diagnosis and treatmentEarly acute management in adults with spinal cord injury: a clinical practice guideline for health-care professionalsCost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.Cumulative and temporal associations between antimicrobial prescribing and community-associated Clostridium difficile infection: population-based case-control study using administrative data.Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole.The prevalence of pantoprozole associated thrombocytopenia in a community hospital.Protective Effect of Carvacrol against Gut Dysbiosis and Clostridium difficile Associated Disease in a Mouse Model.Acid suppressive agents and risk of Mycobacterium tuberculosis: case-control study.Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study.Identification of novel risk factors for community-acquired Clostridium difficile infection using spatial statistics and geographic information system analyses.Clostridium difficile infection in older adultsPostoperative Clostridium difficile-associated diarrhea.Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implicationsIncidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study.Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency MedicineProton pump inhibitor discontinuation in long-term care.
P2860
Q24634086-CA08C1CC-2BAB-4625-B344-566B2DEE6631Q24669995-FDFA6736-187C-45F6-99AB-06E6B797CA07Q26740028-7BC0B7C1-0602-42DD-A46B-581F861CECAFQ26768234-AE5546AC-A4ED-4B5F-9022-1BDF6C29B6FAQ26823000-718E6109-69A1-429E-9D51-62384B1F7BD6Q26849521-487C003A-E191-46CE-9F55-7768D51FDDD9Q27302851-03C4D8AE-E640-495C-BF25-AE72E2E3D2E5Q28072682-0AB97D29-E69F-4E1C-80FD-1D53C3D7C767Q28073805-B4E5B811-C1F4-4197-816D-B6C72960896AQ28077618-C9722A64-5CB5-4045-A400-71E6B28C05D6Q28212695-1275DFA0-DB32-419D-8BA3-95D035E6A9E1Q28289675-5D9F4646-85FC-4F37-91B5-73C455C30DDBQ28388621-C2C3428F-ABCB-478D-B02C-B3DAA3479025Q28552854-A9065BA7-6099-4C49-8CC4-C14EFA2DEB02Q28607773-0F179602-B220-4E9D-8AB8-43F48B1D88FDQ28743438-D67E6B99-CB34-4484-A9D7-ACB7FB432A35Q28750385-4620516F-7A0B-4321-8FB5-5FB1E27EF983Q28762962-AC372052-851F-4943-B174-E274B6CC273EQ29248906-8DF02BF1-297A-499F-BB7E-6106DA0514D3Q30226865-C928EA47-BEDE-45CE-B7BF-326671B1A73DQ30229124-BB7DDDCD-5935-408D-AFA5-1E5ECCB66556Q30229530-1031B2BB-F33D-427F-91BE-1AC8583FAF76Q30244040-E227626F-C1EC-4AD0-B8B0-34830197CF7EQ30316981-CCC85721-272D-4E1A-8679-4DA91B4222ADQ30440562-A91E609D-E283-44FA-A79C-B49B67019020Q30619561-0730127D-5D02-45FC-8B70-9B38EAC295E7Q31150338-4ECDF718-CFC5-4C6E-A088-47C89E4D9CC6Q33276804-04420754-226A-4F78-B388-807743885B95Q33338273-8ED1C4DB-8667-421B-8718-EF64F68777EEQ33376318-E5BFE9A5-06DE-4A97-8579-E6C8355E05A5Q33586133-6677017C-CE8F-49E7-A480-0CE749D43D45Q33646565-24BFD91B-35C8-4CF2-AFAE-E49B87CE1F8FQ33666086-1C732F3A-E8F3-4A59-B037-22E49EBE469AQ33693904-F31B9E02-1810-443E-9141-F077D8205092Q33771594-EA2E3859-F31B-4477-B7FC-238A5A81B0AAQ33915343-50B4E294-0160-403F-8AA8-CBB1D82E99F4Q33949498-FFA7B04D-6B8A-4C2E-AFDC-310D2110A24BQ33962541-2279C465-8DA6-403E-939E-BAE5FB010D25Q33974292-39377ABA-905D-464F-ACBC-0D14BF893C9BQ34007345-AF8BE225-9FCD-41BC-85D7-374410380E35
P2860
Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Use of gastric acid-suppressiv ...... difficile-associated disease.
@en
type
label
Use of gastric acid-suppressiv ...... difficile-associated disease.
@en
prefLabel
Use of gastric acid-suppressiv ...... difficile-associated disease.
@en
P2093
P356
P1476
Use of gastric acid-suppressiv ...... m difficile-associated disease
@en
P2093
Alan N Barkun
Samy Suissa
Sandra Dial
P304
P356
10.1001/JAMA.294.23.2989
P407
P577
2005-12-01T00:00:00Z